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Dried Blood Spot Proteomics: Surface Extraction
of Endogenous Proteins Coupled with Automated
Sample Preparation and Mass Spectrometry Analysis
Nicholas J. Martin,1 Josephine Bunch,2 Helen J. Cooper1
1School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
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Abstract. Dried blood spots offer many advantages as a sample format including
ease and safety of transport and handling. To date, the majority of mass
spectrometry analyses of dried blood spots have focused on small molecules or
hemoglobin. However, dried blood spots are a potentially rich source of protein
biomarkers, an area that has been overlooked. To address this issue, we have
applied an untargeted bottom-up proteomics approach to the analysis of dried
blood spots. We present an automated and integrated method for extraction of
endogenous proteins from the surface of dried blood spots and sample
preparation via trypsin digestion by use of the Advion Biosciences Triversa
Nanomate robotic platform. Liquid chromatography tandem mass spectrometry of
the resulting digests enabled identification of 120 proteins from a single dried blood spot. The proteins
identified cross a concentration range of four orders of magnitude. The method is evaluated and the results
discussed in terms of the proteins identified and their potential use as biomarkers in screening programs.
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Introduction
The analysis of dried blood spots (DBS) by massspectrometry has become increasingly routine in clinical
and pharmaceutical laboratories. There are many advantages
to using DBS over whole blood samples. They are easier to
store and transport than whole blood. Analytes preserved
within a dried blood spot can be stable for years at ambient
conditions [1] and can be eluted in solvents for later
analysis. Many infectious agents such as blood borne viruses
(e.g., HIV) are deactivated upon drying in the filter paper
and so there are fewer biohazards associated with DBS than
whole blood [2]. DBS also require very little sample (~20
μL of blood), which is advantageous when dealing with
newborns or small mammals [1]. DBS can be collected via
finger or heel prick, meaning there is no need for a specially
trained phlebotomist or collection facility (i.e., samples can
be taken by the patient in their own home [3]).
Mass spectrometry was first applied to the analysis of
DBS samples in 1991 by Millington et al. [4] They used fast
atomic bombardment (FAB) mass spectrometry to quantify
derivitized esters of amino acids and acylcarnitines in DBS,
with applications for PKU and medium chain acyl-coenzyme
A dehydrogenase deficiency (MCAD) screening in new-
borns. The advent of electrospray ionisation led to multiple
reaction monitoring (MRM) assays that detect underivatized
metabolites, allowing for higher sample throughput. Many
screening programs use a single-stage multi-analyte ap-
proach, where multiple markers of multiple diseases can be
screened in a single analysis [5]. Mass spectrometry-based
screening assays from DBS are now available for PKU,
MCAD [6], maple syrup urine disease [7] , homocystinurea
[8], and lyososomal storage disorders [9].
The pharmaceutical industry uses DBS in pharmacoki-
netic studies. Identification and quantitation has now been
achieved for a range of drugs and their metabolites, as
reviewed in [2]. More recently, DBS pharmaceutical
analysis has coupled direct surface sampling with ambient
ionisation. A variety of methods that have been trialled,
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including desorption electrospray ionization (DESI) [10],
paperspray ionization [11], surface sealing sampling probe
(SSSP) [12], and liquid extraction surface analysis (LESA)
[13]. These methods have helped increase the throughput of
DBS analysis, eliminating the need for any pretreatment or
lengthy elution stages.
Despite the recent revolution in mass spectrometry-
based proteomics, the DBS mass spectrometry field is
almost entirely limited to the analysis of small molecule
metabolites. Reports of protein analysis by mass spec-
trometry from DBS are scarce, and typically focus on the
analysis of hemoglobin. MS/MS analysis of tryptic digests
of samples eluted from DBS was demonstrated by Daniel
et al. [14] and later by Boemer et al. [15] They performed
both quantitative and qualitative analyses of hemoglobin
by use of an MRM approach. Edwards et al. demonstrated
direct surface sampling of DBS via liquid extraction
surface analysis coupled with top-down mass spectrome-
try for the analysis of hemoglobin variants [16, 17]. Away
from hemoglobin, the field is even more limited. In 2008,
De Wilde et al. [18] demonstrated an MRM assay for the
quantification of cerruloplasmin, a biomarker for Wilson’s
disease, from samples eluted from DBS. The assay gave
comparable results to that of an immunoassay, but has not
yet been taken to a population screening level. Kehler et
al. reported MRM-based quantification of the 39-amino
acid peptide exedin-4 that had been spiked into whole
blood from monkeys and spotted onto a DBS card [19].
Sleczka et al. [20] used a similar MRM assay to quantify
therapeutic proteins, administered intravenously, from
DBS. Blood samples were pipetted onto filter card to
form DBS and quantified against isotopically-labeled
standards that had been spiked into the sample after the
digestion. More recently, Chambers et al. [21] demon-
strated a multiplexed MRM approach for the quantifica-
tion of proteins eluted from DBS. From a panel of 60
human blood proteins, it was possible to quantify 37.
While that study successfully analyzed multiple proteins,
to date there has been no untargeted bottom-up proteo-
mics analysis of DBS. Considering the wide body of
research on the human plasma proteome [22, 23], DBS
have been overlooked as a potential source of biomarkers
[24]. Plasma is considered to be one of the most
important proteomes from a clinical perspective [25].
DBS could offer a more convenient sampling method and
could potentially be used in many different clinical assays
where blood proteins act as biomarkers.
Here, we present an untargeted bottom-up proteomic
analysis of DBS. Our method involves extraction of
intact proteins via automated surface sampling of the
DBS coupled with automated sample preparation (trypsin
digestion), both performed by use of the Advion Bio-
sciences Triversa Nanomate. The resulting peptide di-
gests were analyzed by LC MS/MS. Over 120 proteins
were identified, covering known concentration ranges of
over four orders of magnitude.
Materials and Methods
The work was approved by the University of Birmingham
STEM Ethical Review Committee (ERN_12-0782A). Nor-
mal adult DBS specimens were collected via finger prick
onto standard NHS blood spot (Guthrie) cards, Ahlstrom
grade 226 filter paper (ID Biological Systems, Greenville,
SC, USA) and dried overnight. Conditions in the laboratory
remained within a temperature 23–24 °C and a humidity of
21 %–26 %. Three DBS were analyzed.
Automated Trypsin Digestion
Samples were mounted onto a 96-well microtitre plate (Abgene
PCR plate; Thermo Scientific, Loughborough, UK) and placed
in the Triversa Nanomate chip-based electrospray device
(Advion Biosciences, Ithaca, NY, USA). One of the 96 wells
contained 50 mM NH4HCO3 (Fisher Scientific, Loughbor-
ough, UK), and a second contained 0.1 μg/μL trypsin (Trypsin
Gold; Promega, Southampton, UK). The three DBS were
sampled and digested in parallel to demonstrate the capability
for multiplexing the method.
Surface sampling of the DBS and trypsin digestion was
performed by use of the advanced user interface (AUI) feature
of the ChipSoft Manager software, which controls the Triversa
Nanomate. The sampling/digestion routine was based on
robotic arm movements (X, Y, Z) of the Nanomate probe,
and is illustrated in Figure 1. Liquid extraction surface analysis
(LESA): seven μL of 50 mM NH4HCO3 was aspirated from
the solvent well. The robotic arm relocated to a position above
the DBS and descended approximately 0.8 mm above the
sample. Six μL of the solution was dispensed onto the DBS to
form a liquid microjunction. The liquid microjunction was
maintained between the probe tip and the DBS surface for 4 s to
allow diffusion of analytes into the solvent. Five μL were re-
aspirated and dispensed into a clean well in the microtitre plate.
The conductive pipette tip was then ejected, and a clean tip
selected. Four and a half μL of trypsin solution was aspirated
from the trypsin-containing well and dispensed into the sample
well. (The 0.45 μg aliquot of trypsin used in this digestion
equates to a 1/20 ratio of enzyme to protein. Protein
concentration was calculated via a Bradford assay from a
separate surface extraction). After the enzyme was added, the
sample wasmixed by one aspiration and dispense cycle of 4 μL
and the second tip was ejected. The sample was incubated at
40 °C for 1 h by use of the temperature control unit of the
Triversa Nanomate. At 30 min and 1 h of incubation, a further
7.5 μL of 50 mM NH4HCO3 was aspirated from the solvent
well and added to the sample well, in order to account for
evaporation of the solvent.
LC MS/MS
Once digestion was complete, samples were analyzed by LC
MS/MS. The microtitre plate was removed from the Triversa
Nanomate and placed in the autosampler of the HPLC
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system (Ultimate 3000; Dionex, Thermo Fisher Scientific,
Loughborough, UK), which is coupled to a Thermo Fisher
Orbitrap Velos ETD mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) via the Triversa Nanomate.
Five μL aliquots were injected onto a Pepmap 100, C18
100 μm nanoviper trap (Thermo Fisher Scientific, Lough-
borough UK) for online desalting. The trap was treated to a
5 min wash cycle with 0.1 % formic acid prior to injection
onto the analytical column. This online desalting stage was
performed with the aim of eliminating any off-line purifica-
tion prior to LC MS/MS analysis, thus reducing the need for
manual intervention. Peptides were separated on a Pepmap
100 reversed phase C18 75 μm, 3 μm, 100 Å (Thermo Fisher
Scientific, Loughborough, UK) by use of a 30 min 3.2 %–
44 % ACN (J. T. Baker, The Netherlands) gradient at a flow
rate of 0.35 μL/min. Samples eluted into the mass
spectrometer via the Triversa Nanomate chip-based
nanoelectrospray device. Ionization voltage was 1.4 kV,
gas pressure was 0.3 PSI, and capillary temperature was
250 °C. Mass spectrometry analysis was performed via a
‘top 7’ CID method, in which a survey scan was followed by
CID fragmentation of the seven most abundant precursor
ions. Survey scans were acquired in the Orbitrap with a m/z
range of 350–2000, a resolution of 60,000 at m/z 400, and an
automatic gain control (AGC) target of 1×106 charges. CID
was performed in the ion trap (AGC target: 30,000 charges)
and a collision energy of 35 %. Dynamic exclusion was
applied ensuring that no peptide of the same precursor m/z
was selected within 60 s. All singly-charged peaks and those
multiply-charged peaks with an intensity of G5000 charges
were rejected for fragmentation.
Data Analysis
MS/MS data were searched against the SwissProt human
database (downloaded in December 2012), composed of
20,233 sequences, using the Mascot and Sequest algorithms
in Proteome Discoverer 1.3. For both algorithms, the following
(b) (c) (d) (e)
Robotic pipette
(a)
Conductive pipette tip
Dried  blood spot
Solvent well Trypsin well
Microtitre Plate
Liquid microjunction
(g) (h)
To auto sampler
(i) (j) (k)
(f)
Figure 1. Summary of robotic workflow. (a) Starting position: DBS is mounted on the microtitre plate. One well contains
extraction solvent and a second well contains trypsin solution; (b) 7 μL of 50 mMol NH4HCO3 is aspirated from solvent well; (c)
6 μL is dispensed onto DBS surface. Liquid microjunction is maintained between the pipette tip and the DBS surface (for 4 s)
allowing intact proteins to dissolve into solvent; (d) solution of intact proteins (5 μL) is re-aspirated and dispensed into clean
sample well; (e) 4.5 μL of 0.1 μg/μL trypsin solution is aspirated from trypsin well; (f) trypsin solution is added to sample well; (g)
sample is incubated at 40 °C for 1 h. Enzyme digests intact proteins into peptides; (h) and (i) as solvent begins to evaporate
from sample well, additional solvent (7.5 μL) is aspirated from solvent well and added to sample well [(h) and (i) are performed
at 30 min and 1 h]. ( j ) Proteins are digested into peptides after 1 h. (k) Plate is transferred to HPLC autosampler and peptides
are analyzed by LC MS/MS
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parameters were applied: precursor ion mass accuracy 10 ppm,
fragment mass tolerance 0.8 Da, methionine oxidation was
allowed as a dynamic modification, up to two missed cleavages
in the digestion. Peptide false discovery rates were calculated
from a decoy database using the percolator function of
Proteome Discoverer. Data were filtered to a false discovery
rate of 1%. The protein grouping algorithmwas applied, which
grouped all non-unique peptides to the highest scoring protein.
All proteins identified by only one unique peptide were
confirmed manually.
Results and Discussion
LESA extraction of proteins from DBS followed by automated
trypsin digestion and LC MS/MS was performed in triplicate.
The workflow employed is illustrated in Figure 1. The number
of proteins identified in the three replicates was 120, 115, and
107 proteins. (Preliminary experiments [data not shown] in
which the LESA extraction and trypsin digestion were
performed manually and the digest analyzed by direct infusion
MS/MS resulted in identification of hemoglobin α- and β-
chains only, highlighting the need for LC separation). Across
the replicates, 68 proteins were common to all three, with ~80
common between pairs of replicates, see Figure 2. Figure 3a–d
show the results obtained from one of the DBS samples. The
total ion chromatogram, shown in Supplemental Figure 1,
demonstrates that samples prepared via LESA sampling of
DBS and automated trypsin digestion contain peptides of
suitable abundance, but without leading to any overloading of
the HPLC column.
In the example shown in Figure 3, 120 proteins were
identified, and these are summarized in Table 1 and detailed in
Supplemental Table 1. Proteins identified on the basis of single
peptides were checked manually and the CID MS/MS spectra
are shown in Supplemental Figure 2. The proteins identified
include many of the classic plasma proteins, along with
hemoglobin chains and other proteins derived from erythro-
cytes. The proteins identified cross concentration ranges of
over four orders of magnitude in human blood. The most
abundant proteins identified were hemoglobin and albumin,
and the least abundant was protein S100-A9. Hemoglobin
makes up 97 % of the protein in human red blood cells [26].
Albumin has a plasma concentration of 500–800 μmol/L,
whereas protein S-100 A9 has a concentration of 0.05–
0.014 μmol/L [27]. The CID MS/MS spectrum obtained from
[M + 2H]2+ ions of peptide VGAHAGEYGAEALER from
hemoglobin α-chain is shown in Figure 3a. Full peptide
sequence coverage is obtained. Figure 3b and c show MS/MS
spectra obtained from [M + 2H]2+ ions of peptides from
proteins of intermediate concentration in blood: LGVYELLLK
from inter 1 alpha trypsin inhibitor H4 and ALYLQYTDETFR
from cerruloplasmin. Inter alpha trypsin inhibitor H4 has an
plasma concentration of 2–4 μmol/L and cerruloplasmin has a
plasma concentration of 2–5 μmol/[27]. Figure 3d shows the
CID MS/MS spectrum obtained from [M + 2H]2+ ions of
peptide NIETIINTFHQYSVK from protein S100-A9, which
has a low plasma concentration of 0.05–0.014 μmol/L [27].
The categories of proteins identified from the DBS are
illustrated in Figure 4, and detailed in Supplemental Figure 3.
The proteins identified include four hemoglobins, 61 known
plasma proteins [22, 27, 28], 14 structural proteins such as
keratins, 19 proteins of known erythrocyte or platelet origin
[29–31], and 22 proteins of an unknown cellular origin,
eight of which were enzymes. Of the 61 plasma proteins,
there were eight complement proteins such as C3 and C9, 15
transport proteins (e.g., albumin and apolipoproteins), and
All replicates 
64 proteins
Unique in 2
22
2-3 overlap 81 
proteins
Unique in 3 
12
1-3 overlap 81 
proteins
Unique in 1
25 proteins
1-2 overlap 83 
proteins
Figure 2. Reproducibility of identifications. Protein identifications from dried blood spots across the three replicates
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five coagulation factors, including fibrinogen, prothrombin,
and kininogen 1. The remaining plasma proteins were
composed of 10 immunoglobulins and 23 other plasma
proteins, including glycoproteins and protease inhibitors.
Twenty-nine of the 37 proteins quantified by Chambers et al.
[21] in their targeted analysis were identified here. In
addition, two of the proteins targeted but not detected in
that study were identified here.
A large number of the structural proteins identified were
keratinous. Keratin is a common contaminant in proteomics
experiments, originating from dust in the laboratory or the
users themselves contaminating the sample. In this case, the
keratin is likely to originate from the blood collection
method: the blood was acquired via a finger prick, releasing
a skin plug into the blood and onto the card.
Many of the proteins identified are known to be found
in erythrocytes or platelets [29–31]. These include the
hemoglobin proteins and several others, of which many
were enzymes. Examples include carbonic anhydrase,
catalase, and peroxiredoxin 2. There were some proteins
whose exact cellular origin could not be classified. These
include histone H2A and mucin-like protein. Although
not classic plasma proteins or associated with erythro-
cytes, these could originate from other types of blood
Figure 3. (a) CID MS/MS spectrum of peptide VGAHAGEYGAEALER in the +2 charge state, from alpha chain of hemoglobin, a
very high abundance protein. (b) CID MS/MS spectrum of peptide LGVYELLLK in the +2 charge state, from inter alpha trypsin
inhibitor H4, a medium abundance protein. (c) CID MS/MS spectrum of peptide ALYLQYTDETFR in the +2 charge state from
cerruloplasmin, a medium abundance protein and biomarker of Wilson’s disease. (d) CID MS/MS spectrum of peptide
NIETIINTFHQYSVK in the +2 charge state from protein S100 A9, a very low abundance protein
1246 N. J. Martin et al.: Dried Blood Spot Proteomics
cells or merely be a result of tissue leakage into the
blood stream, which is known to account for some of the
lesser abundant proteins in human plasma [25].
Several proteins were identified that could act as bio-
markers in newborn screening programs or other clinical
assays [18, 32, 33]. In addition to hemoglobin, suitable
Table 1. Proteins identified from LC MS/MS run of trypsin digestion of endogenous proteins sampled from surface of DBS
Protein Description Concentration in
Plasma/μmol/L*
Protein Description Concentration in
Plasma/μmol/L *
Hemoglobin subunit beta Ras-related protein Rab-14
Hemoglobin subunit delta Glutathione S-transferase A1
Hemoglobin subunit gamma-1 Ig alpha-1 chain C region 8–50
Hemoglobin subunit alpha Polyubiquitin-C
Protein S100-A9 0.05–0.14 Serum amyloid A-4 protein 4
Apolipoprotein A-I 30–70 Alpha-synuclein
Glyceraldehyde-3-phosphate-dehydrogenase Thioredoxin
Ig kappa chain C region 68–150 Cofilin-1
Carbonic anhydrase 1 Protein DJ-1
Carbonic anhydrase 2 Mucin-like protein 1
Peroxiredoxin-6 Complement C4-B 0.5–2
Protein S100-A6 Ig gamma-3 chain C region 2–16
Keratin, type I cytoskeletal 10 Alpha-1B-glycoprotein 3–5
Complement C3 5–10 Vitronectin 1–3
Serum paraoxonase/arylesterase 1 Gelsolin 3–5
Keratin, type II cytoskeletal 1 Haptoglobin 0–40
Apolipoprotein A-II 30–60 Keratin, type II cytoskeletal 5
Serum albumin 500–800 Lactotransferrin
Ig gamma-1 chain C region 68–150 Semenogelin-2
Flavin reductase Ig kappa chain V-I region Lay 68–150
Keratin, type I cytoskeletal 9 Trypsin-1
Keratin, type II cytoskeletal 2 epidermal Angiotensinogen 1
Alpha-1-antitrypsin 18–40 Keratin, type II cytoskeletal 6A
Keratin, type I cytoskeletal 13 Heat shock protein beta-1
Apolipoprotein C-III 6–20 Prothrombin 1.5
Dermcidin Histidine-rich glycoprotein 1-3
Protein S100-A8 0.05–0.14 Apolipoprotein E 0.6–2
Inter-alpha-trypsin inhibitor heavy chain H4 2–4 Ig lambda chain V-III region LOI 36–48
Bisphosphoglycerate mutase Alpha-enolase
Peroxiredoxin-2 Zinc-alpha-2-glycoprotein 0.8–1.6
Actin, cytoplasmic 1 Alpha-1-antichymotrypsin 4–9
Histone H2A type 1-H Apolipoprotein-L1 0.2
Inter-alpha-trypsin inhibitor heavy chain H2 2–3 Kininogen-1 3
Ceruloplasmin 2–5 Adenylate kinase isoenzyme 1
Apolipoprotein C-II 2–7 Fibrinogen alpha chain 10–27
Vitamin D-binding protein Delta-aminolevulinic acid dehydratase
Nucleoside diphosphate kinase A Alpha-2-HS-glycoprotein 9-30
Serotransferrin 25–45 Plasma protease C1 inhibitor
Complement factor B Ig gamma-2 chain C region 20–90
Ig kappa chain V-III region SIE 68–150 Arginase-1
Alpha-1-acid glycoprotein 1 9–20 Zymogen granule protein 16 homolog B
Keratin, type II cytoskeletal 2 oral Complement factor H 2–5
GTP-binding nuclear protein Ran Rab GDP dissociation inhibitor beta
Hemopexin 9–20 Heat shock-related 70 kDa protein 2
Catalase 14-3-3 protein theta
Apolipoprotein A-IV 3–6 Plasminogen 2–4
Clusterin N] 1–2 Fibroblast growth factor 2
Alpha-2-macroglobulin 7–17 Liver carboxylesterase 1
Fibrinogen beta chain 10–27 Heparin cofactor 2 1.5
Lysozyme C 0.01–1 Serpin B3
Ig lambda-7 chain C region 68–150 Protein disulfide-isomerase A2
Peroxiredoxin-1 Zinc finger protein 611
Fibrinogen gamma chain 9–24 Apolipoprotein B-100 1–3
Semenogelin-1 Phosphoglycerate kinase 1
Peptidyl-prolyl cis-trans isomerase A Retinal dehydrogenase 1
Apolipoprotein C-I 6–12 Lumican
Purine nucleoside phosphorylase Complement C1s subcomponent 1
Keratin, type I cytoskeletal 14 Plasma kallikrein
Inter-alpha-trypsin inhibitor heavy chain H1 2–4 Ig mu heavy chain disease protein 4–25
Fructose-bisphosphate aldolase A Complement component C9 0.4–1
*Reference concentrations of named protein in healthy human plasma [27]
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candidates include cerruloplasmin, which can act as a
biomarker for Wilson’s disease, a copper transport deficien-
cy [18], and alpha-1-antitrypsin, a biomarker for alpha-1-
antitrypsin deficiency. Alpha-1-antitrypsin deficiency can
result in chronic obstructive pulmonary disease (COPD),
emphysema, and liver failure, and often goes undiagnosed. It
has been suggested that screening of individuals suffering from
COPD for alpha-1-antitrypsin deficiency could be beneficial
[33]. Protein S100 A9 and S100 A8 were the least abundant
proteins identified in this study and have been shown to be
up-regulated in blood plasma in several inflammatory
diseases, such as rheumatoid arthritis, cystic fibrosis, and
bronchitis [34]. As more plasma proteins are beginning
to become associated with more disease states, it is
expected that the number of biomarkers that can be
identified from DBS will increase. For example, pancre-
atic cancer has been associated with increased levels of
alpha-1B-glycoprotein, alpha-2 macroglobulin, comple-
ment C3, complement C9, complement factor H, and
hemopexin, all of which were identified in this study.
As described above, multiple proteins can be successfully
identified from a single dried blood spot via this simple
automated tryptic digestion. The DBS require no pretreatment,
no separate elution from the spot, and no lengthy sample
preparation or cleanup stages. A range of digestion times
(30 min, 1, 2, 4, and 8 h) were investigated. Supplemental
Figure 4 shows representative total ion chromatograms from
each time point. As expected, the amount of undigested protein
observed decreased with digestion time; however, that did not
correlate with increased numbers of protein identified (see
Supplemental Figure 5). The optimum digestion time was 1 h,
which correlates well with the timescale of LC MS/MS
analysis and offers the potential for automated parallel analysis
on a large scale. It is possible that use of proteases with broader
specificity, such as pepsin or proteinase K, might result in
greater numbers of protein identifications on this timescale, and
work in this area is ongoing. It is also worth noting that the
short digestion time may lead to larger proteolytic fragments
for which separation by C18 liquid chromatography is not
ideal. Use of C4 or C8 stationary phase may further increase the
number of protein identifications.
The method also offers advantages in terms of ease-of-use:
the digestion is fully automated and multiple samples can be
digested in parallel, as performed here. Whilst the LC analysis
is not fully integrated with the sample preparation, the only
manual intervention required is to take the microtitre plate out
of the Triversa Nanomate and place it into the HPLC
autosampler. Online desalting was performed to eliminate the
need for any off-line purification and any manual intervention.
A particular advantage of the DBS LESA extraction
method presented here is that it requires very small amounts
of trypsin. The results of a Bradford assay (data not shown)
revealed that 8.7 μg of protein is extracted from the surface
of the DBS using LESA. With only 8.7 μg of protein
extracted from the spot, very little enzyme is required. In
previous studies, Chambers et al. used 3.5 μg of trypsin per
microliter of blood applied to the DBS, totaling 52.5 μg of
enzyme per blood spot [21], Daniel et al. used 25 μg [14] ,
De Wilde et al. used 27.2 μg [18], and Sleczka et al. used
200 μg [20]. The method presented here requires just
0.45 μg of trypsin per sample.
The Triversa Nanomate used for DBS sampling and
sample preparation can be interfaced with most mass
spectrometers. Although this study used the high resolution
Orbitrap mass spectrometer, the instrument of choice for
bottom-up proteomics, it is entirely feasible that the DBS
sampling and sample preparation methods could be employed
in conjunction with other mass spectrometers. For example, it
is possible that MRM assays on triple quadrupole mass
spectrometers could be developed using this approach.
Conclusion
We have demonstrated an automated method incorporating
liquid extraction surface analysis of DBS and trypsin
digestion coupled with LC MS/MS. The results show that
DBS are a suitable sample format for proteomics analyses.
Over 100 proteins were identified in each analysis, crossing
a concentration range of four orders of magnitude. The
lowest known concentration protein identified was S100 A9
(0.05–0.014 μmol/L in plasma). A number of the proteins
identified are potential biomarkers for disease.
The DBS sampling and digestion procedure is quick,
automated, reproducible, requires minimal reagents, and
can be multiplexed. The robotic platform is commercially
available, does not require any specialist programming
skills or any software development, and can be interfaced
with most mass spectrometers. The method could be of
particular use for high throughput analysis and screening
Haemoglobins
3% Erythrocyte/platelet 
proteins
14%
Complement 
proteins
7%
Immunoglobulins
8%
Transport proteins
13%
Coagulation factors
4%
Other plamsma 
Proteins
19%
Keratins and other 
structural proteins
12%
Enzymes
7%
Other/ unassaigned
13%
Figure 4. Categories of proteins identified
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programmes. To achieve this goal, full integration of the
automated sample preparation and LC MS/MS is
required and work in that area is ongoing.
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